🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Can exercise improve quality of life in older cancer patients? Journal of Geriatric Oncology This 12-week remote supervised exercise program led to: ⬆️Improved HRQoL (p=0.001) ⬇️Reduced fatigue, pain, nausea, depression, anxiety, drowsiness ➡️88% adherence ✅ High satisfaction & feasibility

FKSI-23 is a robust patient-reported outcome (PRO) tool developed to assess quality of life in kidney cancer patients. #KidneyCancer #HRQOL #FKSI23 #PRO #Pallative #Oncology #supportivecare @FACITorg Tom Powles Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Paulo G Bergerot Sarah P. Psutka MD MS Brian Rini, MD

Are we doing enough for older adults with cancer? 🚨This scoping review by SIOG & ESMO - Eur. Oncology reveals that geriatric oncology remains largely overlooked in European cancer guidelines. 👉Let’s bridge the gap with tailored, age-inclusive guidance and research! #GeriatricOncology

Prophylactic oophorectomy boosts survival by up to 50% in young women with BRCA mutations! This large international cohort study in The Lancet Oncology shows that risk-reducing surgeries significantly lower not just cancer risk, but mortality rates too. 💡 Genetic risk can turn

Honoured to present my case at the #ESMO Preceptorship on Cancer Care in Elderly Patients in Lugano. A truly inspiring and interactive program. Thank you ESMO - Eur. Oncology, Dr. Giuseppe Banna for the valuable insights, and my mentor Dr. Osman Sütcüoğlu for his constant support.

Proud to present our latest work in The Lancet Regional Health – Europe! The Lancet Reg Health-Europe The Lancet 🚨 We present the first external validation of the PROMISE Score outside Spain and introduce the novel PROMISE–CTI Combined Score (AUC: 0.884 | Sens: 92.4% | Spec: 81.1%) for

New in Journal of Geriatric Oncology What drives decision regret in older men with metastatic castration-resistant prostate cancer (mCRPC)? In this prospective cohort, baseline pain and early treatment discontinuation — not age or frailty — were key predictors. Patient-reported outcomes reveal

Our new study is out in @CancerControl! We explored how patients with cancer view AI in oncology. Hope meets concern — trust, privacy & human touch matter. Grateful to @dryukselurun @emre_yekeduz for their mentorship. 🔗 doi.org/10.1177/107327… #Oncology #AIinHealthcare

Still inspired by my mentoring session with Dr. Cristiane Bergerot at #ASCO25. Her sincere approach, strong vision, and kind guidance made it an unforgettable experience. I had the chance to receive inspiring advice from her on developing myself further in supportive care,

📢 Just published in Journal of the @NCCN ! Our RCT shows that a telehealth GA & #SuppCare Intervention (GAIN-S) improved physical function, mood & QoL in older Brazilians with metastatic cancer William Dale, MD, PhD, FASCO Enrique Soto Areej El-Jawahri Ryan Nipp, MD, MPH, MBA, FASCO jnccn.org/view/journals/…

#MCCRWorkshop Faculty & Fellows, class of 2025! Since 1999, this workshop has fostered innovation, collaboration, and groundbreaking research in clinical cancer. #EORTC ESMO - Eur. Oncology AACR

A real-world comparative effectiveness study of 👉 Atezolizumab + Bevacizumab vs. Tremelimumab + Durvalumab (STRIDE) in advanced hepatocellular carcinoma (#HCC). 🟡 No significant OS difference overall 🟣 Female patients showed better outcomes with Atezo/Beva (HR 1.77, p=0.04)

🎯 Ovarian cancer treatment is entering a new era! In 89% of primary tumors, at least one ADC target (FRα, HER2, CDH6, TROP2, B7-H4) showed high expression. 🔬 Post-chemotherapy expression remained largely stable, opening doors for more durable, personalized ADC strategies in

📢 AIM-HIGH work ❗️❗️❗️ 🔹 Multinational, phase 3, randomised trial. 🔹 236 patients with stage IA-IIA non-squamous NSCLC were included. 🔹 Patients with molecular high risk (high/intermediate score) detected by 14-gene profiling were assigned 1:1 to adjuvant platinum-based KT or

🔬 Surgery or RFA for small HCC? Insights from the SURF-RCT & SURF-Cohort 📄 Published in JCO – June 2025 🔗 doi.org/10.1200/JCO-24… 🧪 This large, dual-arm Japanese study (RCT n=302; Cohort n=753) failed to show a survival benefit of surgery over RFA in patients with HCC ≤3

🎥 Can survivor stories heal distress? In Botswana, over 67% of breast cancer patients reported moderate-to-high distress. This pilot study found that peer-led survivor videos reduced distress and alleviated fear and body image concerns. ✅ Cultural relevance matters. 📉 29%

Emre Yekedüz Ankara Üniversitesi Beliz Bahar Karaoğlan ESMO - Eur. Oncology OncoAlert Yüksel Ürün So true 🌟💫. Soon I’ll have to wait in line to get a photo like this

🔬 Givastomig + Nivolumab + mFOLFOX in mGEC (Phase I/II) 📌 Bispecific CLDN18.2/4-1BB antibody ✅ ORR: 71% (up to 83% in expansion cohorts) ⚙️ Active in both low PD-L1 & low CLDN18.2 🛡️ Well-tolerated at all doses 📈 Deep, durable responses 🧪 Ongoing @ 12 mg/kg (NCT04900818)

🧴 Can early multidisciplinary interventions reduce immune-related skin toxicities in NSCLC? In a recent JCO Oncology Practice study (N=154), a proactive strategy during nivolumab + ipilimumab ± chemo led to: 🔻 Grade ≥3 rash: 21% → 8% 🔻 Systemic steroids: 36% → 10% 🔻

📢 Access to healthcare can be a powerful determinant of patient outcomes This large cohort study published in JCO Global Oncology investigates the impact of treatment funding source on survival in patients with bladder cancer. 📌 Among 6,217 patients: 🔹 5-year OS in